X-PECT Trial is Fully Enrolled

The X-PECT phase III clinical trial has finished recruiting over 430 patients, evaluating perifosine treatment for patients with advanced colorectal cancer who have exhausted standard treatments. The trial compares the effectiveness of adding perifosine to Xeloda® (capecitabine). Led by Johanna Bendell, M.D., from the Sarah Cannon Research Institute in Nashville, TN, the trial is being conducted…  Read More